drug

(alogliptin benzoate + pioglitazone hydrochloride)

Marketedupdated 2mo ago

by Takeda Pharmaceuticals USA Inc

Approved

community read0 votes

indications

investigational

Type 2 Diabetes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

Patent cliff

source: FDA Orange Book

first barrier falls

Jun 27, 2028

~2.0 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (12)

Jun 4, 2029formulationUS 86370792.9y
Jun 4, 2029formulationUS 86370792.9y
Jun 4, 2029formulationUS 86370792.9y
Jun 4, 2029formulationUS 86370792.9y
Jun 4, 2029formulationUS 86370792.9y
Jun 4, 2029formulationUS 86370792.9y
Jun 27, 2028compositionUS 78076892.0y
Jun 27, 2028compositionUS 78076892.0y
Jun 27, 2028compositionUS 78076892.0y
Jun 27, 2028compositionUS 78076892.0y
Jun 27, 2028compositionUS 78076892.0y
Jun 27, 2028compositionUS 78076892.0y

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 53m ago

Found something off?